key: cord-0835129-5wu0zy7d authors: Szabo, Peter A.; Dogra, Pranay; Gray, Joshua I.; Wells, Steven B.; Connors, Thomas J.; Weisberg, Stuart P.; Krupska, Izabela; Matsumoto, Rei; Poon, Maya M.L.; Idzikowski, Emma; Morris, Sinead E.; Pasin, Chloé; Yates, Andrew J.; Ku, Amy; Chait, Michael; Davis-Porada, Julia; Guo, Xinzheng V.; Zhou, Jing; Steinle, Matthew; Mackay, Sean; Saqi, Anjali; Baldwin, Matthew R.; Sims, Peter A.; Farber, Donna L. title: Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19 date: 2021-03-11 journal: Immunity DOI: 10.1016/j.immuni.2021.03.005 sha: 84234c956973b2eb55c33a8cd128cb002307900c doc_id: 835129 cord_uid: 5wu0zy7d Immune response dynamics in COVID-19 and its severe manifestations have largely been studied in circulation. Here, we examined the relationship between immune processes in the respiratory tract and circulation through longitudinal phenotypic, transcriptomic and cytokine profiling of paired airway and blood samples from patients with severe COVID-19 relative to heathy controls. In COVID-19 airways, T cells exhibited activated, tissue-resident, and protective profiles; higher T cell frequencies correlated with survival and younger age. Myeloid cells in COVID-19 airways featured hyper-inflammatory signatures and higher frequencies of these cells correlated with mortality and older age. In COVID-19 blood, aberrant CD163+ monocytes predominated over conventional monocytes, and were found in corresponding airway samples and in damaged alveoli. High levels of myeloid chemoattractants in airways suggest recruitment of these cells through a CCL2-CCR2 chemokine axis. Our findings provide insights into immune processes driving COVID-19 lung pathology with therapeutic implications for targeting inflammation in the respiratory tract. The respiratory virus SARS-CoV-2 has resulted in devastating impacts to the world's 2 population due to morbidity and mortality of COVID-19, as well as the life-altering measures 3 implemented to mitigate spread. While the majority of infected individuals (>90%) develop a 4 self-limiting disease and recover, approximately 5-10% of individuals develop severe respiratory 5 disease marked by lung infiltrates and reduced oxygen saturation, which can progress to acute containing antibodies specific for major lineage determinants and markers for differentiation, 10 tissue residence, activation, and function (see Key Resources Table) , and analyzed by spectral 11 flow cytometry (gating strategy for mononuclear cells shown in Figure S1 ). Principal component Age is a strong independent risk factor for death in COVID-19 (Cummings et al., 2020; 12 Garibaldi et al., 2021). We investigated whether the overall immune cell composition in airways 13 and blood (average of all longitudinal samples obtained for each patient) was altered with age 14 and/or associated with patient outcome. There were statistically significant correlations of age 15 with immune cell frequencies in airways but not with those in blood ( Figure 2A , Figure S2A ). In 16 particular, these was a strong positive correlation of airway myeloid cells with age (Spearman's 17 rho = 0.65), while airway total and CD4 + T cell frequencies were inversely correlated with age 18 (Spearman's rho = -0.56 and -0.69, respectively) ( Figure 2A) . Notably, mortality from severe 19 COVID-19 was exclusive to older patients in the cohort (Figure 2A ). Figure 2B ). The frequencies of other immune cells in airway (B cells, ILC) and blood (T cells, 2 B cells, and ILCs) did not differ between these groups ( Figure 2B , Figure S2A ). We further 3 investigated whether the longitudinal trajectories of immune cell composition in the airway or 4 blood were predictive of outcome, relative to corresponding clinical measurements of disease 5 severity (SOFA scores and P/F ratio). We used a k-means clustering approach (see methods) to 6 classify the temporal dynamics of immune cell frequencies and clinical measurements (Figure 7 2C). The clinical parameters (SOFA score and P/F ratio) and immune cell frequencies in the 8 blood did not predict outcome (~50% success rate), whereas both T and myeloid cell frequencies 9 in the airway were predictive of outcome with a 75% success rate ( Figure 2C ). Together, these 10 results show that frequencies of T and myeloid cells in the airways were associated with age and 11 outcome, suggesting specific roles for these cell populations in COVID-19 disease pathogenesis. Figure S3A ). There was biased expression of CD69, CD103, PD-1, 2 and HLA-DR in the airways while CCR7, CD45RA, and CD127 expression was more prevalent 3 in the blood ( Figure S3A ). 4 To analyze specific subsets of T cells, Phenograph clustering based on marker expression 5 yielded 24 clusters, which were coalesced into 13 denoting biological subsets, functional, and/or 6 activation states in the airway and blood ( Figure 3A ). Compositional analysis shown by UMAP Figure 3B ). 15 Together, these results suggest that T cells are being activated in situ as well as recruited to the 16 respiratory tract. By contrast, T cell subset proportions in the COVID-19 blood were similar to that of 18 healthy controls, with comparable frequencies of naïve, TCM and TEM populations for both 19 CD4 + and CD8 + lineages, though some COVID-19 patients showed an increase in blood CD4 + 20 TEM cells ( Figure 3B , C). Both COVID-19 and healthy blood lacked measurable TRM cells 21 which were compartmentalized exclusively in the airways, consistent with previous studies 22 showing TRM in airway and lungs but not blood during homeostasis (Kumar et al., 2017; 23 1 markers (HLA-DR, PD-1) were highly expressed by T cells specifically in COVID-19 airways, 2 compared to the low level of expression by T cells in COVID-19 blood and in both control sites 3 ( Figure 3D ). Together, these analyses indicate that activated T cells responding to the ongoing 4 infection in severe COVID-19 were localized to the airways and are not present at high levels in 5 circulation -a finding consistent with airway, but not blood T cells associated with improved 6 outcome. We applied similar high-dimensional analysis to identify subsets of myeloid populations 10 in aggregated airway and blood samples from severe COVID-19 patients and healthy controls. Phenograph clustering of myeloid marker expression identified 21 clusters, which were 12 coalesced into 9 clusters based on phenotypic similarity to classical and intermediate monocyte contrast, COVID-19 airway exhibited substantial phenotypic overlap with blood myeloid 2 subsets, suggesting infiltration from blood to airway. In COVID-19 airways, conventional 3 CD163 hi macrophages (blue) were present along with an increased frequency of CD163 lo HLA-4 DR lo (green) and CD86 hi HLA-DR hi cells (yellow) relative to control airways, as well as different 5 monocyte subsets also seen in blood ( Figure 4B , C). In COVID-19 blood, there were stark 6 differences in monocyte phenotypes including a predominance of CD163 hi and HLA-DR lo 7 monocytes that are not significantly present in healthy blood, and additional monocytic subsets 8 that were shared between COVID-19 airway and blood ( Figure 4B , C). This analysis showed 9 major aberrations in the distribution, phenotype and composition of myeloid cells in the airway 10 and blood of severe COVID-19 patients. To further investigate COVID-19-associated features of myeloid cells for each site, we 12 analyzed coordinate expression of antigen-presentation related molecules HLA-DR and CD86, 13 functional myeloid markers CD64 and CD163, and CD14 and CD16 expression, which define expressed by CD163 hi HLA-DR lo monocytes aberrantly present in blood, which was at a lower 20 level compared to healthy airway CD163 hi macrophages ( Figure 4E ). Lastly, COVID-19 airways 21 exhibited a striking reduction of CD16-expressing monocytes denoting an intermediate 22 phenotype (CD14 + CD16 + ) compared to healthy controls ( Figure 4F ). Moreover, all COVID-19 23 J o u r n a l P r e -p r o o f 13 blood monocyte subsets showed a reduction of HLA-DR hi cells relative to their respective 1 healthy controls ( Figure S4B ). Taken together, our results indicate dysregulated monocytes in the 2 blood, alterations of airway macrophages, and evidence for infiltration of aberrant monocyte 3 populations into the airways-a finding consistent with increased airway myeloid cells 4 associated with worse outcome. To dissect the functional states of T and myeloid cells in severe COVID-19, we applied 9 transcriptome profiling by scRNA-seq to daily paired airway and blood samples from 4 patients 10 (total of 126,564 cells, Table S3 ). This scRNA-seq profiling identified immune cell 11 compositions consistent with flow cytometry results, along with additional airway cell types such 12 as epithelial cells and ionocytes ( Figures S5A, B, Figure S6A , B). We performed coordinate 13 analysis of the transcriptomic profile of T and myeloid cells between airways and blood to 14 identify how the immune processes in the respiratory tract were connected to those in circulation. For T cells, scRNA-seq revealed distinct transcriptional profiles expressed by airway 16 compared to circulating T cells, as depicted in UMAP of the aggregated data, and heat maps of LGALS, LAG3, and RBPJ compared to blood T cells ( Figure 5B , Table S5 ). 3 Importantly, airway T cells also showed upregulated expression of multiple genes encoding key 4 cytokines and chemokines, including IFNG, CCL2, and CCL4 compared to those in blood 5 ( Figure 5B ), consistent with an activated and pro-inflammatory state. By contrast, blood T cells Figure 5D ). Together, these results 1 demonstrate that airway myeloid cells exhibit a hyper-inflammatory state, in the expression of 2 multiple cytokines and chemokines for recruitment of immune cells. In particular, airway-3 specific expression of CCL2 transcripts along with biased expression of its receptor CCR2 by 4 blood monocytes reveals a potential mechanism for the observed infiltration of blood-derived 5 monocytes into the airway in severe COVID-19. (Table S2) , using a microfluidic multiplexed 23 J o u r n a l P r e -p r o o f 16 secretome proteomic platform (Farhadian et al., 2020). Overall, we found marked differences in 1 cytokine and chemokine content in the airway compared to plasma as seen in paired samples and 2 at early (day 1) and later (day 3-7) time points ( Figure 6A , Figure S7A , B). Analytes elevated in 3 airways compared to blood include monocyte/macrophage chemoattractants MCP-1 (CCL2), 4 MIP-1α (CCL3), and MIP1β (CCL4), and T cell-associated cytokines granzyme B, IL-7, and 5 TNF-β ( Figure 6A , 6B, Figure S7B ). By contrast, in the blood CCL2 (MCP-1), CCL3 (MIP-1α), 6 granzyme B, TNF-β, and IL-7 were undetectable, while CCL4 (MIP-1β) was present at variable 7 levels across patients ( Figure 6A , B). Both blood and airways contained low and/or variable 8 levels of molecules associated with T cell effector function (perforin, IFN-γ, IL-17, and IL-2), 9 additional innate cytokines (IL-6 and IL-8), and TGF-β ( Figure 6A , B, Figure S7B ). Together, 10 these results show the production of pro-inflammatory chemokines and cytokines in the airway 11 with only a subset of these detected in blood. To define the cellular origin of the soluble mediators detected in each compartment, we 13 analyzed transcript expression for each of the molecules in Figure 6B to the high levels of the respective proteins in airways, while blood myeloid cells expressed 17 lower or undetectable levels of these transcripts ( Figure 6C ). Airway and blood myeloid cells 18 also expressed CXCL8 and TGFB1, consistent with the protein data ( Figure 6C ). In the airways, T cells expressed GZMB, CXCL8, CCL4, PRF, IFNG, and TGFB1 transcripts, which were 20 expressed by blood T cells at lower or variable levels ( Figure 6C ). Airway epithelial cells 21 expressed predominantly CXCL8 transcripts, as well as lower levels of transcripts for IL-7 and 22 several chemokines ( Figure 6C ). Overall, these results demonstrate a highly inflammatory Accumulation of monocytes/macrophages in the lungs of severe COVID-19 patients 5 We hypothesized that the production of monocyte chemoattractants in the airway may 6 recruit dysregulated blood monocytes into the lung. We therefore examined T and myeloid cells In this study, we obtained paired respiratory and blood samples from patients with severe Limitations of this study include a small cohort size and short sampling window (up to 10 10 days after intubation) during a course of prolonged acute illness. Due to the small sample size 11 and the older age of patient who died, we were not able to separate the role of age and immune 12 cell frequencies with outcome. However, the strong inverse correlation that we observed between 13 age and lower T cell frequencies suggests that there are age-related changes in airway immunity 14 that may explain the higher mortality observed in older adults with severe COVID-19. Moreover, 15 we only studied respiratory and blood responses in severe COVID-19, and not in more mild 16 manifestations of the disease, and it will be interesting in future studies to incorporate upper 17 respiratory sampling to assess immunity during a resolved infection. 1 We wish to express our gratitude to the Medical ICU nurse champions, Cora Garcellano, Tenzin 2 Drukdak, Harriet Avila Raymundo, Lori Wagner, and Ricky Lee, who led the efforts to obtain Statistical significance was calculated using a one-way ANOVA followed by a Tukey HSD and 8 indicated by ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05. Processing of blood samples and isolation of PBMCs from COVID-19 patients 6 Whole blood collected in heparinized vacutainers was centrifuged at 400 x g for 10 min at room 7 temperature (RT) to isolate plasma, which was then stored at −80 °C for subsequent analysis. Table S3 . (Table S7 ). Uninfected lung 4 sections were obtained from deceased organ donors who were brain dead due to trauma >2 years first the data was filtered to remove any noise using quantile gates; events that fell below 0.01% 4 of marker expression intensity were removed from the sample. Following initial filtering, data 5 from COVID-19 and healthy samples was merged after subsetting 60,000 events from each 6 COVID-19 airway and blood sample, 120,000 events from each healthy blood sample, and all 7 events from healthy airway samples. Any sample with fewer than 1000 events was removed The resulting dataset was used for downstream analysis. 16 We ran PCA analysis at sample level using mean expression of markers in each sample, PCA loadings provided in Table S3 . Next, we ran UMAP dimensionality reduction (k = 60) on Processing of scRNA-seq Data 13 We used kallisto v0.46.2 in "BUS" mode to pseudo-align the raw reads for each sample to a Figure S5 . In the main text, we present focused analyses on myeloid cells, T cells, and 20 epithelial/club/goblet cells from the airway. To further refine our annotation, we re-clustered the 21 cells annotated as each of these three cell types separately using the methods described above. 22 We then re-analyzed the enrichment of cell type-specific markers in the resulting new clusters. J o u r n a l P r e -p r o o f 42 As expected, this focused re-analysis of each of these three major populations identified 1 additional putative multiplet clusters and cells that we likely mis-clustered in the initial merged 2 analysis. We conducted two rounds of re-clustering for each of these three major cell types to 3 produce a refined annotation. The top of Figure S6A shows a gene expression heatmap for key 4 marker genes in the merged airway data set colored by patient and cell type annotation. We 5 repeated the above procedure for the merged blood scRNA-seq profiles including a focused re-6 clustering analysis of the cells that we originally annotated as myeloid and T cells for refinement. The bottom of Figure S6A shows a gene expression heatmap for key marker genes in the merged 8 blood data set colored by patient and cell type annotation. 11 We generated merged UMAP embeddings for the blood and airway T cells ( Figure 5A ) and the 12 blood and airway myeloid cells ( Figure 5C ). In each case, we first identified genes that were Table S8 . For both myeloid and T cells, we took all of the cells in the data set that we had annotated 10 as each of these two cell types and used the drop-out score method described above to generate a 11 list of putative, highly variable marker genes for each patient. Next, we generated a merged 12 count matrix across all patients for a given cell type, which we normalized using the pooling Harmony-corrected principal components. These embeddings appear in Figure 5 . For the differential expression analysis between blood and airway myeloid cells and 3 between blood and airway T cells, we used the Mann-Whitney U-test approach described above. 4 We removed genes on the blacklists described above for each cell type prior to subsampling, 5 normalization, and statistical testing. We also restricted this analysis to protein-coding genes and 6 removed all T cell receptor and immunoglobulin variable regions. We performed differential 7 expression separately on each pair of matched airway and blood samples (there are 12 patient 8 time points for which we have matched samples). Stringent criteria were used to select the 9 differentially expressed genes displayed in the heatmaps in Figure 5 . For the myeloid cell 10 heatmap in Figure 5 , a gene had to be differentially expressed with a fold-change of at least 4 in 11 either direction and FDR<0.001 in at least 9 of the 12 matched sample pairs. For the T cell 12 heatmap in Figure 5 , we applied the first two criteria, but required them in only 6 of the 12 13 matched sample pairs. Results for all of the pairwise differential expression analyses comparing 14 airway and blood T and myeloid cells can be found in Table S5 and Table S6 , respectively. Differences in means between two sample groups were compared using two-tailed t-tests or two-16 tailed Mann-Whitney U tests, except when testing specific directed hypotheses (one-tailed). Table S8 . Related to Figures 5-7 . Blacklisted genes for a given cell type for the scRNA-seq 6 analysis. • Airways show localized immune responses correlating to age and outcome in COVID-19 • Airway T cells are activated and resident while myeloid cells are hyperinflammatory COV022B1 COV022B2 COV022B3 COV026B2 COV026B3 COV026B6 COV026B7 COV027B1 COV028B2 COV028B3 COV028B4 COV028B6 COV022A1 COV022A2 COV022A3 COV026A1 COV026A2 COV026A3 COV026A4 COV026A5 COV026A6 COV026A7 COV027A1 COV028A2 COV028A3 COV028A4 COV028A6 COV022 COV026 COV027 COV028 TRDC COV022 COV026 COV027 COV028 CD14 CD163 CD68 FCGR3A ITGAV MARCO MRC1 CD1D CD244 CCR2 CX3CR1 SELL S1PR4 GIMAP2 APOE C3 C1QB C1QC CCR5 CCL2 CCL3 CCL4 CCL7 CCL18 CCL20 CCL23 CSF1 CXCL1 CXCL2 CXCL3 CXCL5 HLA-DQA IL10 IFNG IL10 IL13 IL15 IL17A IL2 IL4 IL5 IL6 IL7 CXCL8 IL9 CXCL10 CCL2 CCL3 CCL4 PRF1 TNFRSF9 TGFB1 TNF C CSF2 GZMB IFNG IL10 IL13 IL15 IL17A IL2 IL4 IL5 IL6 IL7 CXCL8 IL9 CXCL10 CCL2 CCL3 CCL4 PRF1 TNFRSF9 TGFB1 TNF Diverse macrophage populations 2 SARS-CoV-2 Transcriptome Immunity to respiratory viruses Fast, sensitive and accurate integration of single-17 cell data with Harmony Human T Cell Development, Localization, 20 and Function throughout Life